Long-term Follow-up of Patients with Multiple Endocrine Neoplasia Type 1

  • SAKURAI Akihiro
    Department of Aging Medicine and Geriatrics, Shinshu University Graduate School of Medicine Department of Preventive Medicine, Shinshu University School of Medicine
  • KATAI Miyuki
    Department of Aging Medicine and Geriatrics, Shinshu University Graduate School of Medicine
  • YAMASHITA Koh
    Department of Aging Medicine and Geriatrics, Shinshu University Graduate School of Medicine
  • MORI Jun-ichiro
    Department of Aging Medicine and Geriatrics, Shinshu University Graduate School of Medicine
  • FUKUSHIMA Yoshimitsu
    Department of Preventive Medicine, Shinshu University School of Medicine
  • HASHIZUME Kiyoshi
    Department of Aging Medicine and Geriatrics, Shinshu University Graduate School of Medicine

この論文をさがす

抄録

Whether early surgical treatment of non-functioning pancreas islet cell tumor (NFPT) provides a favorable quality of life and life expectancy in patients with multiple endocrine neoplasia type 1 (MEN1) remains controversial. We analyzed the long-term clinical courses and surgical outcomes of 14 Japanese patients with MEN1-associated NFPTs. NFPTs smaller than 20 mm in diameter did not show any apparent growth over a long monitoring period. Furthermore, these small NFPTs did not metastasize to regional lymph nodes or the liver. On the other hand, the development of additional NFPTs or metastasis was found in five of six patients with large (35 mm or larger) NFPTs. Among the seven patients who underwent a partial pancreatectomy, six patients developed impaired glucose tolerance or diabetes. The accumulation of more prospective data is needed to clarify the optimal surgical indications for patients with NFPTs, especially among the Japanese population, which has a relatively low insulin secretion potency compared with non-Hispanic white and African-American populations.<br>

収録刊行物

  • Endocrine Journal

    Endocrine Journal 54 (2), 295-302, 2007

    一般社団法人 日本内分泌学会

被引用文献 (2)*注記

もっと見る

参考文献 (59)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ